BIONOMICS LTD-ADR (BNOX) Fundamental Analysis & Valuation

NASDAQ:BNOX • US09063M2052

Current stock price

0.2531 USD
+0.01 (+4.2%)
At close:
0.4002 USD
+0.15 (+58.12%)
After Hours:

This BNOX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BNOX Profitability Analysis

1.1 Basic Checks

  • In the past year BNOX has reported negative net income.
  • In the past 5 years BNOX always reported negative net income.
  • BNOX had a negative operating cash flow in each of the past 5 years.
BNOX Yearly Net Income VS EBIT VS OCF VS FCFBNOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -131.15%, BNOX is doing worse than 82.94% of the companies in the same industry.
  • BNOX has a worse Return On Equity (-175.51%) than 66.79% of its industry peers.
Industry RankSector Rank
ROA -131.15%
ROE -175.51%
ROIC N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
BNOX Yearly ROA, ROE, ROICBNOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BNOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNOX Yearly Profit, Operating, Gross MarginsBNOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -50K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BNOX Health Analysis

2.1 Basic Checks

  • BNOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for BNOX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BNOX Yearly Shares OutstandingBNOX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
BNOX Yearly Total Debt VS Total AssetsBNOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -11.22, we must say that BNOX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -11.22, BNOX is doing worse than 77.38% of the companies in the same industry.
  • A Debt/Equity ratio of 0.05 indicates that BNOX is not too dependend on debt financing.
  • The Debt to Equity ratio of BNOX (0.05) is worse than 61.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -11.22
ROIC/WACCN/A
WACC10.42%
BNOX Yearly LT Debt VS Equity VS FCFBNOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.81 indicates that BNOX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.81, BNOX is in line with its industry, outperforming 45.06% of the companies in the same industry.
  • A Quick Ratio of 3.81 indicates that BNOX has no problem at all paying its short term obligations.
  • The Quick ratio of BNOX (3.81) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.81
Quick Ratio 3.81
BNOX Yearly Current Assets VS Current LiabilitesBNOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BNOX Growth Analysis

3.1 Past

  • BNOX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -115.72%.
  • BNOX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.62%.
  • The Revenue for BNOX have been decreasing by -64.58% on average. This is quite bad
EPS 1Y (TTM)-115.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-86.62%
Revenue growth 3Y-8.9%
Revenue growth 5Y-64.58%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BNOX will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.76% on average per year.
  • BNOX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.41% yearly.
EPS Next Y33.83%
EPS Next 2Y28.37%
EPS Next 3Y-16.76%
EPS Next 5YN/A
Revenue Next Year-80.75%
Revenue Next 2Y-45.51%
Revenue Next 3Y118.41%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BNOX Yearly Revenue VS EstimatesBNOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 20M 40M 60M
BNOX Yearly EPS VS EstimatesBNOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. BNOX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BNOX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNOX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNOX Price Earnings VS Forward Price EarningsBNOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNOX Per share dataBNOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • BNOX's earnings are expected to decrease with -16.76% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.37%
EPS Next 3Y-16.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNOX Dividend Analysis

5.1 Amount

  • No dividends for BNOX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BNOX Fundamentals: All Metrics, Ratios and Statistics

BIONOMICS LTD-ADR

NASDAQ:BNOX (12/23/2024, 8:00:01 PM)

After market: 0.4002 +0.15 (+58.12%)

0.2531

+0.01 (+4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-21
Earnings (Next)N/A
Inst Owners16.93%
Inst Owner Change-78.02%
Ins Owners38.23%
Ins Owner Change0%
Market Cap4.94M
Revenue(TTM)22.05K
Net Income(TTM)-31.85M
Analysts82.5
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)37.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-34.81%
Revenue NY rev (3m)-34.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 224.14
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-3.12
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.93
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -131.15%
ROE -175.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.81
Quick Ratio 3.81
Altman-Z -11.22
F-ScoreN/A
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-115.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y33.83%
EPS Next 2Y28.37%
EPS Next 3Y-16.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-86.62%
Revenue growth 3Y-8.9%
Revenue growth 5Y-64.58%
Sales Q2Q%N/A
Revenue Next Year-80.75%
Revenue Next 2Y-45.51%
Revenue Next 3Y118.41%
Revenue Next 5YN/A
EBIT growth 1Y-136.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.65%
OCF growth 3YN/A
OCF growth 5YN/A

BIONOMICS LTD-ADR / BNOX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIONOMICS LTD-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to BNOX.


What is the valuation status of BIONOMICS LTD-ADR (BNOX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONOMICS LTD-ADR (BNOX). This can be considered as Overvalued.


How profitable is BIONOMICS LTD-ADR (BNOX) stock?

BIONOMICS LTD-ADR (BNOX) has a profitability rating of 0 / 10.